Do analysts recommend DOMH or CDXS?

Codexis has a consensus target price of $5.00, suggesting a potential upside of 122.22%. Given Codexis' stronger consensus rating and higher probable upside, analysts plainly believe Codexis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Codexis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, DOMH or CDXS?

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dominari $123.10M 0.52 -$22.43M -$4.03 N/A Codexis $70.39M 2.91 -$43.97M -$0.37 N/A

Is DOMH or CDXS more profitable?

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Codexis -40.97% -68.09% -23.72%

Do analysts prefer AGEN or DOMH?

Agenus currently has a consensus price target of $23.00, indicating a potential upside of 698.61%. Given Agenus' stronger consensus rating and higher possible upside, equities analysts clearly believe Agenus is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, AGEN or DOMH?

Agenus has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Agenus $114.20M 1.05 $120K $1.59 1.81 Dominari $123.10M 0.52 -$22.43M -$4.03 N/A

Is AGEN or DOMH more profitable?

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Agenus 50.49% -31.66% 42.71% Dominari -31.37% -206.20% -155.26%

Do analysts prefer FBIO or DOMH?

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 462.91%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FBIO or DOMH more profitable?

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Dominari -31.37% -206.20% -155.26%

Do analysts recommend DOMH or SGMO?

Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is DOMH or SGMO more profitable?

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dominari -31.37% -206.20% -155.26% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Do analysts rate CRIS or DOMH?

Curis currently has a consensus price target of $17.00, suggesting a potential upside of 8,160.45%. Given Curis' stronger consensus rating and higher probable upside, equities analysts plainly believe Curis is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curis 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CRIS or DOMH?

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curis $9.44M 0.85 -$7.58M -$1.19 N/A Dominari $123.10M 0.52 -$22.43M -$4.03 N/A

Is CRIS or DOMH more profitable?

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Curis -80.29% N/A -181.57% Dominari -31.37% -206.20% -155.26%

Dominari (DOMH) Competitors

$2.82 -0.24 (-7.84%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$2.92 +0.11 (+3.72%)

As of 06/25/2026 07:14 PM Eastern

Compare

DOMH vs. CDXS, AGEN, FBIO, SGMO, and CRIS

Should you buy Dominari stock or one of its competitors? MarketBeat compares Dominari with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dominari include Codexis (CDXS), Agenus (AGEN), Fortress Biotech (FBIO), Sangamo Therapeutics (SGMO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.

How does Dominari compare to Codexis?

Dominari (NASDAQ:DOMH) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Codexis has a consensus target price of $5.00, suggesting a potential upside of 122.22%. Given Codexis' stronger consensus rating and higher probable upside, analysts plainly believe Codexis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.5% of Dominari shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 55.3% of Dominari shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Codexis had 2 more articles in the media than Dominari. MarketBeat recorded 3 mentions for Codexis and 1 mentions for Dominari. Dominari's average media sentiment score of 1.89 beat Codexis' score of 0.62 indicating that Dominari is being referred to more favorably in the media.

Company	Overall Sentiment
Dominari	Very Positive
Codexis	Positive

Dominari has a net margin of -31.37% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Codexis	-40.97%	-68.09%	-23.72%

Dominari has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.52	-$22.43M	-$4.03	N/A
Codexis	$70.39M	2.91	-$43.97M	-$0.37	N/A

Dominari has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market. Comparatively, Codexis has a beta of 2.48, indicating that its stock price is 148% more volatile than the broader market.

Summary

Codexis beats Dominari on 10 of the 16 factors compared between the two stocks.

How does Dominari compare to Agenus?

Agenus (NASDAQ:AGEN) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Agenus has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agenus	$114.20M	1.05	$120K	$1.59	1.81
Dominari	$123.10M	0.52	-$22.43M	-$4.03	N/A

Agenus has a net margin of 50.49% compared to Dominari's net margin of -31.37%. Agenus' return on equity of -31.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agenus	50.49%	-31.66%	42.71%
Dominari	-31.37%	-206.20%	-155.26%

Agenus has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Agenus currently has a consensus price target of $23.00, indicating a potential upside of 698.61%. Given Agenus' stronger consensus rating and higher possible upside, equities analysts clearly believe Agenus is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

61.5% of Agenus shares are owned by institutional investors. Comparatively, 42.5% of Dominari shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 55.3% of Dominari shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Agenus had 1 more articles in the media than Dominari. MarketBeat recorded 2 mentions for Agenus and 1 mentions for Dominari. Dominari's average media sentiment score of 1.89 beat Agenus' score of 1.52 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Agenus	Very Positive
Dominari	Very Positive

Summary

Agenus beats Dominari on 13 of the 16 factors compared between the two stocks.

How does Dominari compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Fortress Biotech has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.59	$6.82M	$3.17	0.95
Dominari	$123.10M	0.52	-$22.43M	-$4.03	N/A

In the previous week, Fortress Biotech had 1 more articles in the media than Dominari. MarketBeat recorded 2 mentions for Fortress Biotech and 1 mentions for Dominari. Dominari's average media sentiment score of 1.89 beat Fortress Biotech's score of 1.87 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Very Positive
Dominari	Very Positive

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 462.91%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Fortress Biotech is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Fortress Biotech has a beta of 1.22, meaning that its share price is 22% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Dominari	-31.37%	-206.20%	-155.26%

Summary

Fortress Biotech beats Dominari on 13 of the 16 factors compared between the two stocks.

How does Dominari compare to Sangamo Therapeutics?

Dominari (NASDAQ:DOMH) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Dominari has a net margin of -31.37% compared to Sangamo Therapeutics' net margin of -310.81%. Dominari's return on equity of -206.20% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dominari	-31.37%	-206.20%	-155.26%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

In the previous week, Sangamo Therapeutics had 3 more articles in the media than Dominari. MarketBeat recorded 4 mentions for Sangamo Therapeutics and 1 mentions for Dominari. Dominari's average media sentiment score of 1.89 beat Sangamo Therapeutics' score of 0.48 indicating that Dominari is being referred to more favorably in the media.

Company	Overall Sentiment
Dominari	Very Positive
Sangamo Therapeutics	Neutral

Sangamo Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Dominari has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Dominari has higher revenue and earnings than Sangamo Therapeutics. Dominari is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dominari	$123.10M	0.52	-$22.43M	-$4.03	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

42.5% of Dominari shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 55.3% of Dominari shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Sangamo Therapeutics beats Dominari on 10 of the 16 factors compared between the two stocks.

How does Dominari compare to Curis?

Curis (NASDAQ:CRIS) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Dominari has a net margin of -31.37% compared to Curis' net margin of -80.29%. Curis' return on equity of 0.00% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curis	-80.29%	N/A	-181.57%
Dominari	-31.37%	-206.20%	-155.26%

30.0% of Curis shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 5.8% of Curis shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Curis has a beta of 3.05, indicating that its stock price is 205% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, Curis had 2 more articles in the media than Dominari. MarketBeat recorded 3 mentions for Curis and 1 mentions for Dominari. Dominari's average media sentiment score of 1.89 beat Curis' score of 1.13 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Curis	Positive
Dominari	Very Positive

Curis currently has a consensus price target of $17.00, suggesting a potential upside of 8,160.45%. Given Curis' stronger consensus rating and higher probable upside, equities analysts plainly believe Curis is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curis	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curis has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curis	$9.44M	0.85	-$7.58M	-$1.19	N/A
Dominari	$123.10M	0.52	-$22.43M	-$4.03	N/A

Summary

Curis beats Dominari on 10 of the 16 factors compared between the two stocks.

Get Dominari News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DOMH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DOMH vs. The Competition

Export

Metric	Dominari	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$69.20M	$3.01B	$6.61B	$12.27B
Dividend Yield	N/A	1.77%	2.67%	5.88%
P/E Ratio	-0.70	18.82	26.01	23.97
Price / Sales	0.52	337.04	540.43	100.50
Price / Cash	N/A	56.53	46.33	53.91
Price / Book	0.66	4.12	10.51	6.32
Net Income	-$22.43M	$64.45M	$3.57B	$337.22M
7 Day Performance	-16.32%	0.08%	0.81%	-1.23%
1 Month Performance	-12.42%	-0.44%	0.22%	-0.63%
1 Year Performance	-52.20%	23.45%	30.83%	27.95%

Dominari Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DOMH Dominari	1.1146 of 5 stars	$2.82 -7.8%	N/A	-49.2%	$69.20M	$123.10M	N/A	4
CDXS Codexis	3.1776 of 5 stars	$2.48 -0.4%	$5.00 +101.6%	-10.4%	$226.33M	$70.39M	N/A	250
AGEN Agenus	3.6296 of 5 stars	$2.98 -8.3%	$23.00 +671.8%	-41.6%	$135.34M	$114.20M	1.87	440
FBIO Fortress Biotech	2.9055 of 5 stars	$2.93 +2.4%	$17.00 +480.2%	+67.8%	$95.01M	$63.26M	0.92	170	Positive News
SGMO Sangamo Therapeutics	1.8599 of 5 stars	$0.17 +3.0%	$5.50 +3,135.3%	N/A	$70.43M	$39.55M	N/A	480

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DOMH) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dominari (DOMH) Competitors